Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics
GET POWR RATINGS... FREE!
COCP Stock Price Chart Interactive Chart >
COCP Price/Volume Stats
| Current price | $1.85 | 52-week high | $7.43 |
| Prev. close | $1.87 | 52-week low | $1.74 |
| Day low | $1.82 | Volume | 8,500 |
| Day high | $1.89 | Avg. volume | 54,771 |
| 50-day MA | $2.30 | Dividend yield | N/A |
| 200-day MA | $3.37 | Market Cap | 15.02M |
Cocrystal Pharma, Inc. (COCP) Company Bio
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Latest COCP News From Around the Web
Below are the latest news stories about COCRYSTAL PHARMA INC that investors may wish to consider to help them evaluate COCP as an investment opportunity.
Cocrystal Pharma Announces Participation in Virtual Investor EventsBOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community events: Noble Capital Markets’ J.P. Morgan Healthcare Conference Takeaways hosted by ChannelChek featuring an interview with Noble Capital Market’s managing director and senior biotechnology analyst Robert LeBoyer discussing management’s perspective on the market environment for biotechnology companies a |
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal Pharma" or "the Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to crea |
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza ABOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study. CC-42344 is a broad-spectrum antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. The randomized, double-controlled Phase 1 study was conducted in Australia to evaluate the safety, tolerability and pharmacokinetics (PK) of CC- |
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022 underway in San Diego. The presentation, “Novel Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was delive |
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza ACocrystal Pharma Inc (NASDAQ: COCP) announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the ongoing Phase 1 study. CC-42344 is a broad-spectrum oral antiviral for pandemic and seasonal influenza A. The randomized, double-controlled, dose-escalating Phase 1 study in Australia was designed to assess the safety, tolerability, and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults. Related: Cocrystal Pha |
COCP Price Returns
| 1-mo | -10.19% |
| 3-mo | -6.09% |
| 6-mo | -43.76% |
| 1-year | -73.41% |
| 3-year | -79.98% |
| 5-year | -97.18% |
| YTD | -5.13% |
| 2022 | -75.00% |
| 2021 | -52.21% |
| 2020 | 174.47% |
| 2019 | -86.24% |
| 2018 | -40.00% |
Continue Researching COCP
Here are a few links from around the web to help you further your research on Cocrystal Pharma Inc's stock as an investment opportunity:Cocrystal Pharma Inc (COCP) Stock Price | Nasdaq
Cocrystal Pharma Inc (COCP) Stock Quote, History and News - Yahoo Finance
Cocrystal Pharma Inc (COCP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...